Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine patient characteristics and dose titration patterns of real-world semaglutide (Wegovy) users. RESEARCH DESIGN AND METHODS: We used a population-based cohort study including Danish adults who filled semaglutide prescriptions from 12 December 2022 to 31 December 2023. Outcomes were patient characteristics, prescriber type, and dose titration patterns. RESULTS: We identified 110,748 individuals (median age 49 years; 70% female) filling 773,708 prescriptions for semaglutide. General practitioners initiated treatment in 86%. Common comorbidities included hypertension (30%), dyslipidemia (17%), and arthrosis (17%). Only 13% reached the maximum dose of 2.4 mg by their fifth prescription, while 5.7% stopped after the first prescription. Few users (10%) followed recommended dose increases every 4 weeks. Overall, 25% filled at least one prescription of 2.4 mg, while 33–48% continued with the 1.0-mg dosage from the fourth prescription onward. CONCLUSIONS: Real-world semaglutide users generally resembled trial participants, but few follow the dose titration schemes tested in premarket clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a Danish population‐based cohort study of 110 749 initiators of semaglutide for obesity, about 50% persisted for one year. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Real‐world studies demonstrate high discontinuation rates of GLP‐1RAs (20%–50%) within the first year, and the use of much lower doses than those evaluated in clinical trials.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Notably, only 10% followed the recommended semaglutide dose increases every four weeks, and only 12% reached the recommended target dose of 2.4 mg by their 5th prescription, with one in three users continuing with the low 1.0 mg dose for a prolonged time. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Notably, only 10% followed the recommended semaglutide dose increases every four weeks, and only 12% reached the recommended target dose of 2.4 mg by their 5th prescription, with one in three users continuing with the low 1.0 mg dose for a prolonged time. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
In the citing paper
“Notably, only 10% followed the recommended semaglutide dose increases every four weeks, and only 12% reached the recommended target dose of 2.4 mg by their 5th prescription, with one in three users continuing with the low 1.0 mg dose for a prolonged time. 37”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Thygesen, L. C., Daasnes, C., Thaulow, I., & Brønnum-Hansen, H. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811399956 · Cited by 1,084
Van Spall, H. G. C., Toren, A., Kiss, A., & Fowler, R. A. (2007) · JAMA · doi:10.1001/jama.297.11.1233 · Cited by 1,055
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Self-citationCagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Noureddin, M., Harrison, S. A., Loomba, R. S., Alkhouri, N., Chalasani, N., Sheikh, M. Y., Tomah, S., Gutierrez, J. A., Urbina, S., Suschak, J. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02114-2 · Cited by 66
Determinants of adherence to obesity medication: A narrative review
Sharma, A. M., Birney, S., Crotty, M., Finer, N., Segal‐Lieberman, G., Vázquez‐Velázquez, V., & Vrijens, B. (2025) · Obesity Reviews · doi:10.1111/obr.13885 · Cited by 42
“39 Persistence may also be lower in people using OMs compared with medications for the other listed chronic diseases (Table 1).”
Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70004 · Cited by 35
“12 Similarly, we found only 22% of our patients received at least one prescription for 2.4 mg semaglutide, although 55% reached 2 mg or higher.”
InfluentialLifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“One Danish study showed 86% of physicians reported prescribing semaglutide [76].”
Jensen, S. D., Gualano, B., Andreassen, P., Scagliusi, F. B., SturtzSreetharan, C., & Brewis, A. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0005516 · Cited by 26
“Real-world cohort studies are noting that few patients follow the GLP-1RA titration schemes devised from premarket clinical trials [18].”
Sørensen, M. S., Pottegård, A., Andersen, N. E., Thomsen, R. W., & Lundby, C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16222 · Cited by 18
Self-citationScragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Self-citationGraabæk, T., Nguyen, N. T., Sørensen, M. S., & Lundby, C. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70069 · Cited by 16
“During the first year, almost 111 000 Danish adults initiated semaglutide treatment for weight loss, with general practitioners issuing prescriptions for 9 out of 10 users [11].”
InfluentialCauses and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“Dose-escalations and/or micro-dosing are employed in clinical practice to avoid withdrawal in people facing gastrointestinal discomfort and other issues 66,67 .”
Sex Differences in Obesity and Its Treatment
Ghanta, A., Wilson, E., & Chao, A. M. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01601-z · Cited by 20
“Similarly another population-based study showed that 70% of users of semaglutide are women [69 ].”
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
Oral semaglutide for the treatment of obesity: a retrospective real-world study
Krajnc, M., Kuhar, N., & Koceva, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593334 · Cited by 20
“In a large real-world study, only 10% of users followed recommended dose increases for subcutaneous semaglutide but they generally resembled trial participants (29).”
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“Weekly injections deter some individuals, and gastro-intestinal side effects such as nausea or vomiting can delay or prevent dose escalation 343–345 .”
Sustained Weight Loss With Combined LEAP2 and Semaglutide Treatment in Mice
Holm, S. K., Johansen, V. B. I., Ranea‐Robles, P., Svendsen, C., Merrild, C., Rohlfs, R., Conte, M. L., Hogendorf, W. F. J., Merkestein, M., Zaykov, A. N., et al. (2025) · Diabetes · doi:10.2337/db24-1056 · Cited by 15
Hviid, K. V. R., Banasik, K., Mortensen, L. H., Madsbad, S., Strandberg‐Larsen, K., Geiker, N. R. W., Westergaard, D., & Nielsen, H. S. (2026) · Human Reproduction Open · doi:10.1093/hropen/hoag015 · Cited by 20
“In Denmark, as 70% of users of weight loss medication are women, it would be inevitable that inadvertent periconceptional GLP-1 RA exposure would occur (Ladebo et al. , 2024).”
Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance
Brufani, C., & Morviducci, L. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf011 · Cited by 11
Homoródi, N., Varga, É., Szabó, Z., Sztanek, F., & Harangi, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112595 · Cited by 15
“In contrast, SGLT2 inhibitors are administered at fixed doses, simplifying their use [94].”
Ulrich, F. S., Napoli, N., Nielsen, M. F., & Burden, A. M. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70535 · Cited by 10
“17,24 We illustrate counts with percentages receiving a specific dose, along with the median time since initiation and corresponding IQR at each prescription number (e.g., first, second, etc.).”
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
“…nearly 50% of real-world users discontinue GLP-1 receptor agonist therapy within the first year, often due to adverse effects, including nausea [ 173], there is an urgent need for novel treatments that cause fewer side effects while maintaining or improving weight loss efficacy to enhance…”
Al‐Qaaneh, A. M., Qunaibi, E. A., Al-Fraihat, N. A., Abu-Aisheh, B. E., Rabea, S., Aloul, A. A., Matahen, R., & Annabi, F. A. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s549716 · Cited by 9
Vilsbøll, T., Kumar, D. A., Aiello, L. P., Rönnbäck, C., Stellfeld, M., & Larsen, L. M. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328729 · Cited by 8
Shaping the future of cardiometabolic innovation: advances and opportunities
Clemmensen, C., Gerhart‐Hines, Z., Schwartz, T. W., Zierath, J. R., & Sakamoto, K. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01343-5 · Cited by 7
Pampanelli, S., Terzoni, S., Pantanetti, P., Loreto, C. D., Mazzieri, A., Cangelosi, G., Alberti, S., Badiali, C., Grandone, I., Migliarelli, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70538 · Cited by 8
“29 32 The most commonly reported reasons for discontinuation include cost, side effects, and unsatisfactory weight loss.”
Tinkering with weight loss medication in clinical encounters: An ethnographic study
Jensen, S. D., Sandbæk, A., Bruun, J. M., & Andreassen, P. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118538 · Cited by 6
Bachmakova, M., Buyukbabani, M. B., Dranseika, V., Brown, R. C. H., Devolder, K., Ryan, N., Savulescu, J., Everett, J. A. C., Hannikainen, I. R., & Earp, B. D. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118657 · Cited by 10
Levy, M. E., Telis, N., Barrett, K. M. S., Bolze, A., Stoller, D. A., Chapman, C. N., Chahal, C. A. A., Judge, D. P., Olson, D. A., Grzymski, J. J., et al. (2024) · medRxiv · doi:10.1101/2024.10.31.24316494 · Cited by 7
“27 Additionally, many patients discontinue quickly.”
Farrell, A., Paris, T., Parr, E. B., George, E. S., Howell, J. A., Croagh, C. M. N., Sutherland, T., Page, M., McKelvie, P. A., Thompson, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101787 · Cited by 6
“39,40 This pragmatic use of the VLED to induce clinically significant weight loss followed by low-dose semaglutide to prevent weight regain presents a more affordable alternative to high-dose GLP-1RA monotherapy with lower medication costs and improved tolerability.”
Parker, G., Morris, M. D., Heggie, J. R., Cooper-Leavitt, E. F., Clark, C. J., Reynolds, A. P., Smith, H. A., Wendel, C. P., Jensen, W. J., Morris, T. C. M., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060313 · Cited by 4
“However, a significant limitation is the associated loss of lean body mass, which may account for 25–40% of total weight lost [4,5].”
Amirthalingam, P., Alatawi, O. S., Hamdan, A. M., Aljabri, A. M., Alqifari, S. F., Alshareef, H. M., Hakami, F. A. M., Albalawi, N. S., Albrahimi, H. M. A., Alanazi, S., et al. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s534534 · Cited by 4
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 4
Guldhammer, A., Drivsholm, T., Tomova-Olsen, S. A., & Jensen, K. T. (2026) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2026.2636584 · Cited by 2
“…after the first prescription, increasing to 25% after the fifth prescription, where several continued treatment at a lower dosage than prescribed [39]. these numbers align with the perception of weight loss medication as a temporary weight loss booster in our material, emerging from the…”
GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?
Kosjerina, V., & Rossing, P. R. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.001 · Cited by 2
Hasan, M. R., Shil, K. K., & Morshed, M. S. (2026) · Health Science Reports · doi:10.1002/hsr2.71745 · Cited by 1
“A population‐based Danish study found that only 10% could increase the dose every 4 weeks, and nearly 50% continued with a weekly dose of only 1.0 mg due to side effects [31].”
InfluentialSaeed, Z. I., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.006 · Cited by 1
Skandov, M. D., Christensen, K. M., Dalin, D. A., Unkerskov, J., Brønden, A., Lund, M. A. V., Christensen, M., & Karstoft, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71092 · Cited by 1
“…and relative weight loss was compared using one-way Analysis of Variance (ANOVA) with Tukey's post hoc tests comparing individuals in three distinct dose groups ( ≤ 1 mg/week, > 1– ≤ 1.7 mg/week and > 1.7– ≤ 2.4 mg/week) representing typical maintenance dosing intervals in clinical practise [5].”
InfluentialOfili, S. C., & Chen, H. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.2.166 · Cited by 3
Lischka, J., Torbahn, G., Vallis, M., Mörwald, K., Gomahr, J., Forslund, A., Stenlid, R., Manell, H., Bergsten, P., Geiersberger, S., et al. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70122
“More often, doses are adjusted in response to adverse events, with slower escalation strategies employed to enhance tolerability and quality of life [48].”
Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review
Bloomgarden, Z. T. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70248 · Cited by 1
“In the Ladebo Danish registry, only 13% of semaglutide users reached 2.4 mg, with the majority stabilizing at 1.0 mg [7].”
InfluentialHormonal Contraception and Initiation of Semaglutide Therapy
Bager, M. D., Wood-Kurland, H. K., Sørensen, K. K., Kragholm, K. H., Andersen, M. O., Torp-Pedersen, C. T. P., & Yazdanfard, P. D. W. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.24382
Gomon, Y. М., Колбин, А. С., Spichakova, E. A., & Reznik, V. A. (2026) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-gcp-0022
Milani, I., Parrotta, M. E., Chinucci, M., Franzò, E., Gintoli, E., Franco, F., Sbraccia, P., Guglielmi, V., & Capoccia, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819337 · Cited by 1
Tournayre, S., Bonnet, J., Anitcheou, J., Faivre, M., Boegner, C., Jalek, A., Jullien-Durmont, D., Rouzic, C. L., Attalin, V., Myzia, J., et al. (2026) · Journal of Medical Internet Research · doi:10.2196/80119 · Cited by 1
“Our 48-week persistence rate of 74.3% and full-dose attainment rate of 87.3% substantially exceed figures from large administrative datasets, where 1-year persistence is typically 32% to 50% and full-dose attainment is ≤15% [6-10].”
InfluentialLünswilken, P., Worobiec, K., Braun, L. S., Altrogge, J., Schenk, A., Jegodzinski, L., Wilms, B., Marquardt, J. U., & Meyhöfer, S. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag350
Saeed, Z. I., Donnelly-Boylen, M., Hammershøy, L., Bilal, I., ROLIN, A., Micheelsen, A., Knop, F. K., LAURSEN, J. V., & Aroda, V. R. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100328
RetractedMajanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
Vergniory-Trueba, O., & Lobato, C. T. (2026) · Healthcare · doi:10.3390/healthcare14193355
“In other European settings, population-based studies have begun to characterize treat-ment patterns and patient experiences with GLP-1 receptor agonists, but these studies have generally focused on specific agents or selected aspects of treatment use [13].”
Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women
Deanfield, J. E., Wong, J. L. C., Katsoulis, M., Deanfield, E., Thakkar, R., Patel, R. S., Joy, R., Noble, M. J., & Ryan, D. H. (2026) · Nature Medicine · doi:10.1038/s41591-026-04687-x
Zhang, Y., Chen, Y., Huang, S., Jiang, L., Wang, Y., Ma, J., Deng, R., Du, J., Xia, L., Ma, Y., et al. (2026) · medRxiv · doi:10.64898/2026.10.18.26365821
Makuc, J., & Janić, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218295
Metadata
- Authors
- Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A.
- Affiliations
- University of Southern Denmark (DK)
- 2Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
- University of Copenhagen (DK)
- Corresponding author
- Ladebo, Louise
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-08-06
- Volume
- 47
- Issue
- 10
- Pages
- 1834-1837
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4401362613
- Semantic Scholar
- 2c608147363bef907c9b67b1b269a7ee9fa30a21
- Cited by
- 46
- References
- 14
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 1
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Funders
- Aarhus Universitet
- Aarhus Universitetshospital
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, Wegovy, weight management, obesity treatment, dose titration, real-world prescribing patterns, patient characteristics, general practitioners, medication adherence, prescription refills, comorbidities
- MeSH terms
- Semaglutide, Adult, Aged, Denmark, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.